December 06, 2018
(AOF) – ABIVAX
Abivax has received authorization from the Data Monitoring and Monitoring Committee (DSMB) to continue the extension study of the phase 2a clinical trial in patients with ulcerative colitis. The randomized, double-blind, placebo-controlled clinical induction trial demonstrated good tolerability and statistically significant efficacy based on clinical and endoscopic criteria.
Biom'up successfully completed a private placement of € 7.67 million as part of a capital increase through the issuance of new ordinary shares without pre-emptive subscription rights. The company has placed approximately 1.6 million new shares at a price of 4.80 euros per share, a discount of around 2% compared to the closing price on 5 December 2018 of 4.90 euros per share. The offer represents 12.61% of the share capital of the pre-issuance company.
The Board of Directors of Capgemini co-opted Laura Desmond as a new director on the proposal of the Ethics and Governance Committee chaired by the Lead Independent Director. Laura Desmond is the founder and CEO of Eagle Vista Partners, a strategic consulting and investment firm specializing in marketing and digital technologies. She has also been a member of Adobe's Board of Directors since 2012.
CASINO / NATIXIS
Natixis and Casino have signed an agreement to jointly create an electronic wallet for Cdiscount and to integrate Dalenys as a payment service provider partner of Cdiscount. At the beginning of 2019, Cdiscount customers will be able to use an electronic purse that will offer them a fluid and optimized purchase experience. They will be able to pay in 1 click their purchases (without having to enter their credit card data), choose to pay cash or several times or benefit from cash-back on their purchases.
The cost of electricity will, at a time, be reflected in the bills, warned the CEO of EDF, Jean-Bernard Lévy, on RTL. The leader reacted to the government's decision to freeze rates during the coming winter in response to the "Yellow Vests" protest.
Gecina said that the Paris Court of Appeal had issued a judgment on December 5 stating the end of the appeal that had formed Joaquín Rivero, deceased in 2016, and sentenced in first instance in 2015 to 209 million euros for the harm caused.
Genfit has reported positive results from its Phase 2 study evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC), a chronic liver disease.
The French Inside Secure has signed an exclusive agreement for the acquisition of the American company Verimatrix, an unlisted company based in San Diego, California. The transaction will be completed in cash at an aggregate price of approximately $ 143 million at the date of completion of the transaction (including the reversal of an estimated $ 18 million in net cash), to which will be added potential price supplement payable in the second quarter of 2019 estimated at $ 9 million. Inside Secure says the operation is fully funded.
Latécoère is lowering its financial outlook for 2019 in the wake of start-up costs and additional investments. Thus, the aeronautical equipment manufacturer explains that "the start-up costs of the Interconnection Systems division and the progress of the Transformation plan in the Aerostructures branch will generate a positive recurring operating margin and a negative operating free cash flow."
L'Oréal announces the launch of BOLD (Business Opportunities for L'Oréal Development), a private equity fund intended to take minority stakes in innovative start-ups with high growth potential. "Aiming to invest in new marketing models, R & I, digital, distribution, communication, supply and packaging, this fund will support start-ups by providing their expertise, its network and a mentoring device," says the group.
Novacyt received another major order for Primerdesign's new Primerdesign molecular diagnostics instrument in the fast-growing Chinese market. The order for 100 molecular diagnostic instruments has been prepaid and brings to more than 230 the number of diagnostic instruments sold in the Asia-Pacific region. The genesig q16 is Primerdesign's proprietary molecular test instrument designed to make DNA testing affordable and easy to use.
Recylex has opened new discussions with its financial partners in order to adapt the financing mechanism obtained by the group's German scope in December 2016 (amended in September 2018) to the current and forecast cash generation of the latter. Since the second quarter of 2018, the production of the Group's main furnace (BSF – Bath Smelting Furnace) has experienced a significant slowdown due to the technical adaptations required for its connection with the new reduction furnace.
SpineGuard has entered into a multi-year partnership agreement with Carnot Interfaces to combine its DSG technology with a surgical robot. "We are convinced that our partnership with Carnot Interfaces will lead to major technological breakthroughs that will allow the robot to autonomously and safely drill holes in the human skeleton or even insert implants directly," said Stéphane Bette. , Managing Director of SpineGuard.